Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Idarubicin Appears Equivalent to Dose-Intense daunorubicin for AML Induction

Steven Trifilio, Zheng Zhou, Jayesh Mehta, MD, Colleen Czerniak, Judy Pi, Molly Koslosky, Deborah Greenberg, Mihaela Pantiru, MD, Jessica Altman

Blood (2012) 120 (21): 3581.

https://doi.org/10.1182/blood.V120.21.3581.3581

Published: 2012

Journal Articles

Dose-Intense Etoposide and Cyclophosphamide without Stem Cell Transplantation for the Treatment of Primary Refractory and Relapsed Acute Myeloid Leukemia

Steven Trifilio, Zheng Zhou, Jessica K. Altman, MD, Mihaela Pantiru, MD, Jayesh Mehta, MD

Blood (2012) 120 (21): 4314.

https://doi.org/10.1182/blood.V120.21.4314.4314

Published: 2012

Journal Articles

Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project

Katherine C Allen, PharmD, Amanda H Champlain, MD, Jonathan Cotliar, MD, Steven M. Belknap, MD, Dennis P. West, PhD, Jayesh Mehta, MD, Steven Trifilio

Blood (2012) 120 (21): 1351.

https://doi.org/10.1182/blood.V120.21.1351.1351

Published: 2012

Journal Articles

Mitoxantrone and Etoposide with or without Intermediate-Dose Cytarabine for the Treatment of Patients with Primary Induction Failure or Relapsed Acute Myeloid Leukemia

Steven Trifilio, Alfred Radamaker, Diane Newman, Kathryn Coyle, Katrin Carlson Leuer, Jayesh Mehta, Jessica Kaplan Altman, MD, Olga Frankfurt, MD, Martin S. Tallman, MD

Blood (2010) 116 (21): 2174.

https://doi.org/10.1182/blood.V116.21.2174.2174

Published: 2010

Journal Articles

Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.

Steven Trifilio, Judy Pi, Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Jayesh Mehta

Blood (2007) 110 (11): 4956.

https://doi.org/10.1182/blood.V110.11.4956.4956

Published: 2007

NARROW

Idarubicin Appears Equivalent to Dose-Intense daunorubicin for AML Induction

Dose-Intense Etoposide and Cyclophosphamide without Stem Cell Transplantation for the Treatment of Primary Refractory and Relapsed Acute Myeloid Leukemia

Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project

Mitoxantrone and Etoposide with or without Intermediate-Dose Cytarabine for the Treatment of Patients with Primary Induction Failure or Relapsed Acute Myeloid Leukemia

Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.

Email alerts

ASH Publications

American Society of Hematology

Idarubicin Appears Equivalent to Dose-Intense daunorubicin for AML Induction

Dose-Intense Etoposide and Cyclophosphamide without Stem Cell Transplantation for the Treatment of Primary Refractory and Relapsed Acute Myeloid Leukemia

Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project

Mitoxantrone and Etoposide with or without Intermediate-Dose Cytarabine for the Treatment of Patients with Primary Induction Failure or Relapsed Acute Myeloid Leukemia

Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only